

2024 Honorific Award Winners

The 2024 Honorific Awards were presented by Awards Committee chair, Kerry Ressler, M.D., Ph.D. at the 63rd ACNP Annual Meeting.

Daniel H. Efron Research Award - Recognizing Outstanding Basic Research Contributions to Neuropsychopharmacology

Recipient – Debra A. Bangasser, Ph.D. Georgia State University




Dr. Bangasser is a Distinguished Investigator of the Georgia Research Alliance and Professor of Neuroscience at Georgia State University where she was recently appointed Director of their Center for Behavioral Neuroscience. Dr. Bangasser is a leading expert on how stress contributes to sex-specific vulnerability or resistance to substance use, depression, and anxiety disorders. Based on her scientific contributions, she has been a sought advisor on a range of topics from developing the Research Domain Criteria to inclusion of female subjects in research, including chairing a study group on The Future of Sex Difference Research in Neuropsychopharmacology for the ACNP. Dr. Bangasser is an advocate for diversity in science through her mentoring and public outreach activities. She co-founded the Building Research Independence by Developing Goals and Hands-on Experiences (BRIDGE) program at Temple University to provide research and mentoring opportunities for students from groups historically underrepresented in science. She also co-chaired a Presidential Initiative for the American Psychological Association (APA), the Opening Doors Summit to promote successful transitions of graduate trainees into the workforce, for which she received their prestigious Presidential Citation award in 2014.

Please <u>click here</u> to watch the acceptance video by Debra A. Bangasser, Ph.D. for the Daniel H. Efron Research Award.

Please <u>click here</u> to watch the nominator video by Tracy Bale, Ph.D. for the Daniel H. Efron Research Award.

Recipient – Anna V. Molofsky, M.D., Ph.D. University of California, San Francisco



Dr. Molofsky's groundbreaking research has led to paradigm shifting scientific advances throughout her career. In her graduate studies, she revealed an unexpected pathway through which stem cells in the brain can self-renew and give rise to both neurons and glial cells throughout life, findings that have had a lasting impact in the fields of tissue regeneration, cancer, and aging. In her postdoctoral studies, she revealed a novel molecular mechanism through which astrocytes, structural glial cells of the brain, direct neuronal maturation in a region-specific manner. Her lab's current research combines an ability to bridge basic and translational settings with a deep expertise into the non-neuronal mechanisms that regulate brain development and function. She is a respected leader across disciplines, and is frequently invited to present at meetings ranging from basic and systems immunology, to neuroscience, to psychiatric disease research. Notably, Dr. Molofsky's work has been published in leading scientific journals, including Nature, Science, Cell, Nature Neuroscience, Journal of Neuroscience, among others.

Please <u>click here</u> to watch the acceptance video by Anna V. Molofsky, M.D., Ph.D. for the Daniel H. Efron Research Award.

Statement from the nominator of the Daniel H. Efron Research Award, Michelle Monje, M.D., Ph.D. - "I want to congratulate Anna Molofsky on the very well-deserved honor of the Daniel Efron Award. Dr. Molofsky's beautiful work elucidating immune mechanisms influencing brain development and plasticity relevant to neuropsychiatric symptoms has been nothing short of path-breaking. Her work has and will continue to advance fundamental understanding and therapeutic opportunities that will ultimately improve the lives of people living with psychiatric diseases."

Joel Elkes Research Award - Recognizing Outstanding Clinical Contributions to Neuropsychopharmacology

Recipient – Aristotle N. Voineskos, M.D., Ph.D. University of Toronto



Dr. Voineskos received his BSc at the University of Western Ontario and then went on to earn his M.D. and Ph.D. at the University of Toronto. He completed his fellowship training with a focus on neuroimaging at Harvard Medical School and Brigham and Women's Hospital. Dr. Voineskos' program of research broadly focuses on severe mental illness across the human lifespan, from childhood to late life. His initial work focused on employing advanced multimodal brain imaging and complementary phenotypic data to refine our understanding of schizophrenia and other psychoses with computational data-driven approaches. He became interested in the ultimate application of neuroimaging clinically, and got involved in clinical trials, where he used brain imaging to better understand the effects of pharmacological treatments, along with the targeting of specific circuitry to improve treatment response. More recently he has been involved in pragmatic and implementation trials testing models of care in both academic and community settings, to improve practice, and real-world outcomes. These experiences culminated in a decision to establish a series of large clinical cohorts at CAMH to better understand and characterize longitudinal outcomes across the lifespan, using a precision approach, to open opportunities for prevention and disease modification trials.

Please <u>click here</u> to watch the acceptance video by Aristotle N. Voineskos, M.D., Ph.D. for the Joel Elkes Research Award.

Please <u>click here</u> to watch the nominator video by Zafiris Daskalakis, M.D., Ph.D. for the Joel Elkes Research Award.

Eva King Killam Research Award - Recognizing Outstanding Translational Research Contributions to Neuropsychopharmacology that Focus on Translating Advances from Basic Science to Human Investigations.

Recipient – Sergiu P. Pasca, M.D. Stanford University



Dr. Pasca, the Kenneth T. Norris Jr. Professor at Stanford University, is internationally recognized for developing self-organizing, pluripotent stem-based neural models, such as organoids and assembloids. His revolutionary work has significantly advanced our understanding of neuropsychiatric disorders and revealed crucial mechanisms of brain development and disease. Over the past decade, Dr. Pasca has made transformative discoveries using innovative methods to construct human neural circuits. His pioneering approach enables the investigation of complex cellular interactions and the modeling of brain disorders, offering a unique window into the molecular and cellular processes that underlie neuropsychiatric diseases. Notably, his development of assembloids has provided a platform for studying human neural migration, circuit formation, and disease pathomechanisms. This work has led to insights into conditions such as Timothy syndrome and 22q11.2 deletion syndrome and facilitated potential new therapeutic interventions. Dr. Pasca's dedication to the scientific community is evidenced by his extensive efforts in sharing his methodologies and organizing consensus-building events for fellow researchers. His commitment to open collaboration has had a global impact, shaping the field of molecular psychiatry and setting the stage for future breakthroughs.


Statement from the 2024 Eva King Killam Research Award winner, Sergiu P. Pasca, M.D. - "I am deeply honored to receive the 2024 Eva King Killam Prize and extend my heartfelt

gratitude to the American College of Neuropsychopharmacology for this recognition. This is an incredibly exciting time for neuroscience, as we now have unprecedented approaches to non-invasively study and manipulate human neurons and circuits. The various stem cell models, including the patient-derived neural assembloids and organoids, hold great promise in advancing our understanding of disease biology and unlocking new avenues for therapeutic discovery. I am thrilled to present some of the foundational work leading up to this and the translational potential at the ACNP Annual Meeting in December. I am profoundly grateful to the mentors who shaped my journey and to the brilliant students and postdocs in my lab who carried out the work—many of whom now lead their own labs. This award is a testament to their dedication and creativity. Thank you for this tremendous honor."

Statement from the nominator of the Eva King Killam Research Award, Robert Malenka, M.D., Ph.D. – "It is a pleasure to congratulate Sergiu Pasca, Ph.D. for his well-deserved receipt of the 2024 Eva King Killam Research Award. He has led the way in making seminal contributions to developing self-organizing, pluripotent stem cell-based assembloid and organoid models of the human nervous system. Over the last decade he has systematically and innovatively applied these preparations to advance our understanding of severe neuropsychiatric disorders with the potential of using these approaches to contribute to the development of novel therapeutics for these conditions. Driven by the challenge of studying interconnected circuits and inaccessible cell-cell interactions, Dr. Pasca deserves enormous credit for pioneering the first assembloids—a modular experimental system that involves the controlled assembly of regionalized organoids and multiple cell lineages. Pasca's assembloids have greatly facilitated the study of neural migration, circuit formation, and revealed a surprising ability of neural circuits to self-assemble, ex vivo, from parts. By creating forebrain assembloids, he modeled the migration of interneurons into the cerebral cortex, unveiling unique human features orchestrating their circuit integration. By then combining assembloids with CRISPR screening, Sergiu mapped hundreds of autism-related genes to interneuron development stages, which also revealed an unknown role of the endoplasmic reticulum in migration. He subsequently expanded the capabilities of assembloids to study long-range axonal connectivity including the development of cortico-striatal assembloids; the functional reconstruction of the cortico-spinal-muscle pathway; as well as the creation of four-part ascending somatosensory assembloids, modeling the spinothalamic pathway of pain. Dr. Pasca also extended his assembloid approach to in vivo studies, where he re-constructed human circuits with behavioral outcomes in living systems, marking a milestone in demonstrating behavioral readouts in animals. In his most recent work, he used an assembloid model to test anti-sense oligonucleotide (ASO) treatment of Timothy Syndrome (TS) and showed that intrathecal delivery of the ASO could rescue deficits in vivo in transplanted human TS neurons. These findings provide the groundwork for a potential clinical trial and elegantly demonstrate the power of the approaches he has pioneered. Once again, congratulations Dr. Pasca for your deserving receipt of this prestigious award."

Barbara Fish Memorial Award - Recognizing an ACNP Member who has made an Outstanding Contribution to Basic, Translational, or Clinical Neuroscience

Recipient – Joseph T. Coyle, M.D. Harvard Medical School



Dr. Joseph Coyle, Eben S. Draper Professor Emeritus of Psychiatry and Neuroscience at Harvard Medical School and McLean Hospital, has had a transformative impact on the fields of psychiatry and neuroscience, with a career spanning nearly five decades. His groundbreaking research has centered on the neurobiology of neuropsychiatric disorders, with a focus on glutamatergic neurotransmission and its role in diseases such as schizophrenia and Huntington's disease. A pioneer in the study of glutamate as a neurotransmitter, Dr. Coyle's early work demonstrated glutamate's involvement in synaptic plasticity and neurodegenerative processes. His influential research on NMDA receptor hypofunction has laid the foundation for novel therapeutic strategies for schizophrenia, impacting both academic research and pharmaceutical development. Over his illustrious career, Dr. Coyle has published over 600 scientific papers, significantly shaping our understanding of the molecular and cellular mechanisms underlying mental illness. In addition to his scientific achievements, Dr. Coyle has been a mentor to numerous scientists, many of whom have gone on to become leaders in the field. His dedication to fostering the next generation of researchers and his leadership roles, including serving as President of both the Society for Neuroscience and the ACNP, underscore his enduring influence.

Please <u>click here</u> to watch the acceptance video by Joseph T. Coyle, M.D. for the Barbara Fish Memorial Award.

Please <u>click here</u> to watch the nominator video by Dost Ongur, M.D., Ph.D. for the Barbara Fish Memorial Award.

Recipient - John H. Krystal, M.D. Yale University School of Medicine




Dr. Krystal is the Robert L. McNeil, Jr., Professor of Translational Research, Professor of Psychiatry, of Neuroscience, and of Psychology, Chair of Psychiatry, and Co-Director of the Yale Center for Clinical Investigation (YCCI) at Yale University. He also serves as Director of the Clinical Neuroscience Division of the National Center for PTSD (VA) and Co-Director of the NIAAA Center for the Translational Neuroscience of Alcohol. Dr. Krystal, a psychiatrist by training, has studied the neurobiology and development of treatment of psychiatric disorders during his exemplary research career, at Yale University over the 40-plus years. His research on the effect of ketamine in humans led the reemergence of the human NMDA glutamate receptor antagonist model as a paradigm for studying glutamate synaptic dysfunction relevant to schizophrenia (cited >4000 times). The NMDA and ketamine research work paved the way for the landmark study of randomized placebo-controlled trial that first identified the rapid antidepressant effects of ketamine (cited >4000 times) and inspired the subsequent research leading to the FDA approval of Esketamine, a mechanistically novel antidepressant in over 50 years for antidepressant-resistant symptoms of depression. Dr. Krystal's research has had a significant impact in the field of neuroscience and psychiatry, and his research has been cited > 110,000 times with current Google Scholar H-Index 175. He has co-authored or authored 670 peer-reviewed articles, with many published in top-tier psychiatry and neurology, neuroimaging and basic science journals including Neuron, Science, Nature, Lancet, J of Neuroscience, Biological Psychiatry, JAMA Psychiatry, American Journal of Psychiatry, Neuropsychopharmacology, and many others. Dr. Krystal served as President of the American College of Neuropsychopharmacology, in several national and international roles, including President of the CINP, member of the NIAAA and NIMH Councils, Chair of the NIMH Board of Scientific Counselors, co-leader of Section 7 (Psychiatry/Neurology) of the National Academy of Medicine, as editor-in-chief of *Biological Psychiatry* and co-Director of the Forum on Neuroscience and Nervous System Disorders of the National Academies of Science, Engineering and Medicine, and co-founder of Freedom Biosciences. Dr. Krystal has mentored over 55 young scientists from diverse backgrounds, many of whom have gone on to impactful independent careers including roles as deans, department chairs, scientists with named professorships, lead biotechnology, pharmaceutical and healthcare companies.

Please <u>click here</u> to watch the acceptance video by John H. Krystal, M.D. for the Barbara Fish Memorial Award.

Please <u>click here</u> to watch the nominator video by Eric Nestler, M.D., Ph.D. for the Barbara Fish Memorial Award.

Julius Axelrod Mentorship Award - Recognizes Outstanding Contributions to Neuropsychopharmacology by Mentoring and Developing Young Scientists into Leaders in the Field.

Recipient – Alan Frazer, Ph.D. University of Texas Health Science Center at San Antonio



Dr. Alan Frazer is currently an Adjunct Professor in the Department of Psychiatry at the University of Pennsylvania and Professor in the Department of Pharmacology at the University of Texas Health Science Center at San Antonio in the Long School of Medicine. He received his Bachelor of Science in Chemistry from the Philadelphia College of Pharmacy and Science in 1964 and his Ph.D. in Pharmacology from the University of Pennsylvania in 1969. Dr. Frazer's primary research interest has been the mechanism of action of antidepressant drugs. His preclinical laboratory has focused on improving our mechanistic understanding how chronic antidepressant drug treatments affect the function of two monoaminergic systems, noradrenergic and serotonergic, that are important targets for the clinical effects of antidepressants. His lab has been continuously funded by NIH/VA since 1974 and Dr. Frazer has published 150 primary research papers and 60+ book chapters. Dr. Frazer has an outstanding track record of training the next generation of scientists. In total, he has mentored 7 doctoral students, 14 postdoctoral fellows and residents, and 4 junior faculty members. In addition, he has mentored 16 undergraduate research students, of which 4 were from underrepresented minority backgrounds. Some of Dr. Frazer's mentoring accomplishments include starting a Training Program in Neuropsychopharmacology at the University of Pennsylvania that was supported by the National Institute for Mental Health and for which he was the Director from 1977-1992. After becoming Chair of Pharmacology at the University of Texas Health Science Center at San Antonia, he developed an NIH-supported South Texas Advanced Research Training, Minority Undergraduate training program to provide research experiences and training for underrepresented minority and disadvantaged students as well as students with disabilities.

Please <u>click here</u> to view the acceptance video by Alan Frazer, Ph.D. for the Julius Axelrod Mentorship Award.

Please <u>click here</u> to view the nominator video by Irwin Lucki, M.A., Ph.D. for the Julius Axelrod Mentorship Award.

Dolores Shockley Diversity and Inclusion Advancement Award – Recognizes an Individual and/or Program that has had Outstanding Success Promoting Diversity and Inclusion within the Fields of Basic, Clinical, or Translational Neuroscience

Recipient – Michelle D. Jones-London, Ph.D. National Institute of Neurological Disorders and Stroke




Dr. Jones-London received her BS in Biology from The Pennsylvania State University before earning her Ph.D. at Penn State School of Medicine and completing post-doctoral work at the University of Pennsylvania, where she identified sex differences in depression- and anxiety-like behavior in serotonin receptor knockout mice. She joined the US Department of Health and Human Services in 2004 through the Emerging Leaders Program, in which she gained experience in the HHS Office of Intergovernmental Affairs and FDA Office of Women's Health Science Program, as well as the Center for Scientific Review and NINDS Office of Communications and Public Liaison at the National Institutes of Health. Dr. Jones-London eventually found a permanent home at the National Institute for Neurological Disease and Stroke (NINDS), where she is currently the Associate Director of the Office of Programs to Enhance the Neuroscience Workforce (OPEN). Her achievements over the last 20 years to improve scientific workforce diversity have had a profound impact on the successes of scientists from historically marginalized and underrepresented backgrounds not just within NINDS but across Neuroscience-focused ICs in the NIH. Most notably, she was the driving force of several funding initiatives aimed at enhancing and retaining diversity at major career transition points. These include the Enhancing Neuroscience Diversity through Undergraduate Research Education (ENDURE) program, which provides neuroscience training to undergraduates from underrepresented backgrounds in preparation for applying to and succeeding in Ph.D. programs; the Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00), which provides support for Ph.D. students to transition into postdoctoral work; the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00), a diversity-focused Pathway to Independence Award for postdocs to transition to tenure-track faculty positions; and part of the steering committee for the NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program, which provides resources to Universities and Institutions that seek to recruit and retain faculty from underrepresented backgrounds. These programs have now funded hundreds of scientists—many of whom are now leaders in their respective fields—demonstrating Dr. Jones-London's measurably immense and lasting effect on the biomedical workforce.

Please <u>click here</u> to view the acceptance video by Michelle D. Jones-London, Ph.D. for the Dolores Shockley Diversity and Inclusion Advancement Award.

Please <u>click here</u> to view the nominator video by Rita Valentino, Ph.D. for the Dolores Shockley Diversity and Inclusion Advancement Award.

Women's Advocacy Award – Recognizes an Individual and/or Program that has had Outstanding Success in the Promotion and Support of Women to Address the Gender Imbalance within the Field of Brain and Behavior Disorders.

Recipient – Karen F. Berman, M.D. NIMH, National Institutes of Health, Intramural Research Program



Dr. Berman is Chief of the Clinical and Translational Neuroscience Branch and Chief of the Section on Integrative Neuroimaging at the NIMH Intramural Research Program. She has been President and Council Member for the Society of Biological Psychiatry (where she served on the Women's Leadership Task Force), an ACNP Council member, and President of the International Organization for Human Brain Mapping. She is a leader in neuroimaging research and is an elected member of the National Academy of Medicine. Dr. Berman began advocating for women scientists as she launched her career, at a time when women comprised less than 15% of her medical school class and 10% of ACNP members. At the NIH Intramural Research Program, she participated in the Cross-NIH and NIMH Women Scientist Advisors Committees and initiated the Women's Task Force when elected to the ACNP Council and co-sponsored the first Women's lunch at the annual meeting. Dr. Berman has mentored 100's of trainees, 70% of them women. Her mentees include post-baccalaureate research fellows; M.D., Ph.D., and M.D./Ph.D. students; and fellow faculty members, many of whom have provided touching personal stories of her support through good times and bad to their eventual professional success.

Please <u>click here</u> to view the acceptance video by Karen F. Berman, M.D. for the Women's Advocacy Award.

Please <u>click here</u> to view the nominator video by Mary Phillips, M.D. for the Women's Advocacy Award.

Paul Hoch Distinguished Service Award - Presented to a Member who has made Unusually Significant Contributions to the College. The Emphasis of this Award is on Service to the College - Not for Teaching, Clinical, or Research Accomplishment.

Recipient – Victoria Arango, Ph.D. NIMH/NIH (retired)



Dr. Arango was the Chief of the Central and Peripheral Interventions Development Branch at the National Institute of Mental Health (NIMH) from 2018-2024. She began her career as an Instructor at Cornell University Medical Center (1986–1989) and advanced through roles as Assistant Professor at the University of Pittsburgh (1989–1994) and then Associate Professor at Columbia University (1994–2000), where she later became a Professor (2000–2018). In 2018, she joined the NIMH. Dr. Arango's pioneering research on the neurobiological correlates of suicide, including groundbreaking postmortem studies, has established her as a leader in the field. She has published over 200 peer-reviewed articles, garnered more than 21,000 citations, and achieved an impressive h-index of 75, reflecting her substantial impact on neuroscience research. Her professional leadership includes serving as President of the Society of Biological Psychiatry, Council member of the Brain & Behavior Research Foundation, and Member of the National Board of Directors of the American Foundation for Suicide Prevention. Dr. Arango has also received numerous awards, including the Senior Research Award from the American Association for Suicide Prevention, the Woman of Achievement Award from the College of New Rochelle, NY, and the Morselli Medal - Lifetime Achievement Award for the Study of Suicide from the International Academy of Suicide Prevention. Since joining ACNP in 1993—at a time when women comprised only 3% of the membership—Dr. Arango has been a driving force for change. She played a pivotal role in advancing women's participation within the College and has actively served on several key committees, including the Membership Committee (three terms), the Program Committee, the Education and Training Committee, the Latin American Task Force, the Women's Task Force and the Underrepresented Minorities (URM) Task Force, now known as the Diversity and Inclusion Committee. Her leadership on the Nominating Committee and as a Council member has been critical in shaping ACNP's direction and policies. Under her guidance, the Diversity and Inclusion Committee has made significant strides toward increasing the representation of underrepresented groups, working to ensure that the College more accurately reflects the diversity of society.

Please <u>click here</u> to view the acceptance video by Victoria Arango, Ph.D. for the Paul Hoch Award.

Please <u>click here</u> to view the nominator video by Judith Ford, Ph.D. and Tamar L. Gur, M.D., Ph.D. for the Paul Hoch Award.

Recipient – Charles B. Nemeroff, M.D., Ph.D. The University of Texas at Austin Dell Medical School



Dr. Nemeroff is widely recognized as one of the nation's most influential psychiatrists, with a remarkable career that includes over 1,200 published research studies. His pioneering work has significantly advanced the understanding of the pathophysiology of post-traumatic stress disorder (PTSD) and depression. Notably, his team has identified critical predictors of vulnerability to these conditions and response to evidence-based treatments, paving the way for more targeted and effective interventions. Through funding from NIH and other mechanisms, Dr. Nemeroff has conducted extensive longitudinal studies on trauma exposure and randomized controlled clinical trials. His groundbreaking research has illuminated the lasting impacts of childhood abuse and neglect on neuroendocrine and neurotransmitter systems, inflammatory pathways, and structural and functional brain imaging. Among his many contributions, Dr. Nemeroff's work on the role of corticotropin-releasing factor in depression and PTSD has been particularly transformative, shaping innovative therapeutic strategies to improve outcomes for trauma survivors. Dr. Nemeroff has a long history of distinguished and continuous service to the ACNP, including membership on the Program and Scientific Communications Committee (1987-1989, 2003-2005), the Ethics Committee (1990-1992, Chair in 1991-1992), Honorific Awards Committee (1991), Credential Committee (2000-2002), History Committee (2006-2009), Liaison Committee (2013-2109, serving as Vice Chair in 2016-2017 and Chair in 2018), the Membership Committee (2016-2018, 2022-2023, serving as Vice Chair in 2022 and Chair in 2023), the Education and Training Committee (2019-2021) and Emeritus Memoriam Committee (2021-present). He is the recipient of Daniel H. Efron award (1987), Julius Axelrod Mentorship Award (2016). He also served as Editor-in-Chief of *Neuropsychopharmacology* from 2001 to 2006, participated in the Medicine Development Task Force (2003) and the Task Force for the 2023 Annual meeting, and chaired the APA Research Colloquium for Young Investigators, overseeing the ACNP Bootcamp.

Please <u>click here</u> to view the acceptance video by Charles B. Nemeroff, M.D., Ph.D. for the Paul Hoch Award.

Please <u>click here</u> to view the nominator video by Alan Schatzberg, M.D. for the Paul Hoch Award.

Media Award - Recognizes Major Contributions to the Education of the Public about Mental Illness and Substance Abuse Research and the Positive Impact of Research on Treatment.





The Ad Council is America's leading nonprofit organization that uses the power of strategic communication to drive social change on our country's most pressing issues. With a current focus on gun violence prevention, combating hate and bias, the overdose crisis and other critical issues, the Ad Council champions causes that improve lives and communities. In 2022, the Ad Council announced its Mental Health Initiative, uniting brands, marketers, media companies and nonprofits to change social norms and create a society that is more open, accepting and proactive when it comes to mental health. The Ad Council's mental health campaigns include "Sound it Out" for middle school families, "Seize the Awkward" for young adults, and "Don't Wait, Reach Out" for veterans. Most recently, the Ad Council created "Love, Your Mind," in collaboration with Huntsman Mental Health Institute, to resonate with people across the U.S. who experience mental health challenges while also holding attitudes and beliefs that may discourage them from seeking help. According to Ad Council research, 62% of adults in the U.S. report having a mental health condition, and of those with a condition, less than half are getting help or treatment. Since launching in fall 2023, "Love, Your Mind" has made an extraordinary impact, garnering 4.3 billion impressions and \$47 million in donated media support. Notable figures, including star athletes across 11 different leagues and organizations, beloved icons from Sesame Workshop like Elmo, and influential media personalities such as Tyler Perry and Stephen A. Smith have partnered with the campaign. The campaign extends beyond media outreach, focusing on creating actionable resources for communities. The campaign website, loveyourmindtoday.org, serves as a robust resource hub, receiving over 1.1 million visits to date. Targeted collaborations with organizations and leaders in various communities, such as farmers, rodeo stars, and gospel music audiences, ensure a culturally relevant and inclusive approach. The Ad Council's communications work to reshape perceptions of mental health and confronting stigma embodies the nature of the Media Award by creating initiatives that build connections with underserved populations and create lasting change in our society.

Please <u>click here</u> to view the acceptance video by Heidi Arthur with The Ad Council for the Media Award.

Please <u>click here</u> to view the nominator video by Mark Rapaport, M.D. for the Media Award.

Public Service Award - Recognizes Substantial Contributions to Affect Public Policies or other Activities Related to Improving the Health of the Public with an Emphasis on Patients with Brain Diseases

Recipient - Senator John Fetterman





United States Senate

WASHINGTON, D. C.

JOHN K. FETTERMAN PENNSYLVANIA

November 21, 2024

Dear American College of Neuropsychopharmacology,

Thank you for presenting me with the 2024 Public Service Award.

As someone who is committed to ensuring that everyone who has faced mental health challenges has access to the same resources and treatment that I did, I was proud to introduce the United States Senate Commission on Mental Health Act of 2024 with Senator Tina Smith. Our goal is to improve access to and affordability of mental health care services across Pennsylvania and the country. I will continue to promote solutions for mental health challenges in my role on the bipartisan Senate Mental Health Caucus.

I thank you for your dedication to advancing the research and education surrounding brain diseases. It is truly an honor to be nominated and receive this award.

Sincerely

John K. Fetterman United States Senator Please <u>click here</u> to view the nominator video by Melissa Brotman, Ph.D. for the Public Service Award.